CTLA4 and melanoma: Ipilimumab (MDX-010, Yervoy; Bristol-Myers Squibb) is a fully human monoclonal antibody against CTLA-4 (cytotoxic T-lymphocyte antigen-4) for the treatment of melanoma patients and was approved by FDA in 2011 7.